Global Escitalopram tablet Market
Global Escitalopram tablet Market

Escitalopram tablet Comprehensive Study by Application (Treatment, Depression, Anxiety Disorder, Others, Research Studies), Patient Age (Adolescent (12- 17 years), Adults (18 above)), Dosage (5mg, 10mg, 15mg, 20mg) Players and Region - Global Market Outlook to 2026

Escitalopram tablet Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 210 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The Global Escitalopram tablet market presents a comprehensive analysis of the Escitalopram tablet market by end-user/application (Treatment, Depression, Anxiety Disorder, Others and Research Studies), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up.

Market Drivers
  • Availability of generic tablets
  • Rise in the population suffering from anxiety


Restraints
  • Serious side effects associated with the Escitalopram tablet


Geographic Segmentation and Analysis
This section of our report presents a realistic picture of the Global Escitalopram tablet industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in geographical region of interest.
The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)

Frequently asked questions:

1. Why many important players are not profiled in the study?
Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.

2. How big is the Escitalopram tablet Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

3. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
Report Objectives / Segmentation Covered
By Application
  • Treatment
  • Depression
  • Anxiety Disorder
  • Others
  • Research Studies
By Patient Age
  • Adolescent (12- 17 years)
  • Adults (18 above)

By Dosage
  • 5mg
  • 10mg
  • 15mg
  • 20mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Availability of generic tablets
      • 3.2.2. Rise in the population suffering from anxiety
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Escitalopram tablet, by Application, Patient Age, Dosage and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Escitalopram tablet (Value)
      • 5.2.1. Global Escitalopram tablet by: Application (Value)
        • 5.2.1.1. Treatment
        • 5.2.1.2. Depression
        • 5.2.1.3. Anxiety Disorder
        • 5.2.1.4. Others
        • 5.2.1.5. Research Studies
      • 5.2.2. Global Escitalopram tablet by: Patient Age (Value)
        • 5.2.2.1. Adolescent (12- 17 years)
        • 5.2.2.2. Adults (18 above)
      • 5.2.3. Global Escitalopram tablet by: Dosage (Value)
        • 5.2.3.1. 5mg
        • 5.2.3.2. 10mg
        • 5.2.3.3. 15mg
        • 5.2.3.4. 20mg
      • 5.2.4. Global Escitalopram tablet Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Escitalopram tablet: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novell Pharmaceutical Labs (Indonesia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. H. Lundbeck A/S (Denmark)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Forest Laboratories Inc. (US)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biofarm (Poland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lupin (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amneal Pharmaceuticals, LLC (US)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceuticals (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Silarx Pharmacueticals (US)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Apotex Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Escitalopram tablet Sale, by Application, Patient Age, Dosage and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Escitalopram tablet (Value)
      • 7.2.1. Global Escitalopram tablet by: Application (Value)
        • 7.2.1.1. Treatment
        • 7.2.1.2. Depression
        • 7.2.1.3. Anxiety Disorder
        • 7.2.1.4. Others
        • 7.2.1.5. Research Studies
      • 7.2.2. Global Escitalopram tablet by: Patient Age (Value)
        • 7.2.2.1. Adolescent (12- 17 years)
        • 7.2.2.2. Adults (18 above)
      • 7.2.3. Global Escitalopram tablet by: Dosage (Value)
        • 7.2.3.1. 5mg
        • 7.2.3.2. 10mg
        • 7.2.3.3. 15mg
        • 7.2.3.4. 20mg
      • 7.2.4. Global Escitalopram tablet Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Escitalopram tablet: by Application(USD Million)
  • Table 2. Escitalopram tablet Treatment , by Region USD Million (2015-2020)
  • Table 3. Escitalopram tablet Depression , by Region USD Million (2015-2020)
  • Table 4. Escitalopram tablet Anxiety Disorder , by Region USD Million (2015-2020)
  • Table 5. Escitalopram tablet Others , by Region USD Million (2015-2020)
  • Table 6. Escitalopram tablet Research Studies , by Region USD Million (2015-2020)
  • Table 7. Escitalopram tablet: by Patient Age(USD Million)
  • Table 8. Escitalopram tablet Adolescent (12- 17 years) , by Region USD Million (2015-2020)
  • Table 9. Escitalopram tablet Adults (18 above) , by Region USD Million (2015-2020)
  • Table 10. Escitalopram tablet: by Dosage(USD Million)
  • Table 11. Escitalopram tablet 5mg , by Region USD Million (2015-2020)
  • Table 12. Escitalopram tablet 10mg , by Region USD Million (2015-2020)
  • Table 13. Escitalopram tablet 15mg , by Region USD Million (2015-2020)
  • Table 14. Escitalopram tablet 20mg , by Region USD Million (2015-2020)
  • Table 15. South America Escitalopram tablet, by Country USD Million (2015-2020)
  • Table 16. South America Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 17. South America Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 18. South America Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 19. Brazil Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 20. Brazil Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 21. Brazil Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 22. Argentina Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 23. Argentina Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 24. Argentina Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 25. Rest of South America Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 27. Rest of South America Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 28. Asia Pacific Escitalopram tablet, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 31. Asia Pacific Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 32. China Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 33. China Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 34. China Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 35. Japan Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 36. Japan Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 37. Japan Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 38. India Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 39. India Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 40. India Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 41. South Korea Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 42. South Korea Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 43. South Korea Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 44. Taiwan Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 45. Taiwan Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 46. Taiwan Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 47. Australia Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 48. Australia Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 49. Australia Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 53. Europe Escitalopram tablet, by Country USD Million (2015-2020)
  • Table 54. Europe Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 55. Europe Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 56. Europe Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 57. Germany Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 58. Germany Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 59. Germany Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 60. France Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 61. France Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 62. France Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 63. Italy Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 64. Italy Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 65. Italy Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 66. United Kingdom Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 68. United Kingdom Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 69. Netherlands Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 70. Netherlands Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 71. Netherlands Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 72. Rest of Europe Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 74. Rest of Europe Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 75. MEA Escitalopram tablet, by Country USD Million (2015-2020)
  • Table 76. MEA Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 77. MEA Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 78. MEA Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 79. Middle East Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 80. Middle East Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 81. Middle East Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 82. Africa Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 83. Africa Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 84. Africa Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 85. North America Escitalopram tablet, by Country USD Million (2015-2020)
  • Table 86. North America Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 87. North America Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 88. North America Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 89. United States Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 90. United States Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 91. United States Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 92. Canada Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 93. Canada Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 94. Canada Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 95. Mexico Escitalopram tablet, by Application USD Million (2015-2020)
  • Table 96. Mexico Escitalopram tablet, by Patient Age USD Million (2015-2020)
  • Table 97. Mexico Escitalopram tablet, by Dosage USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Escitalopram tablet: by Application(USD Million)
  • Table 109. Escitalopram tablet Treatment , by Region USD Million (2021-2026)
  • Table 110. Escitalopram tablet Depression , by Region USD Million (2021-2026)
  • Table 111. Escitalopram tablet Anxiety Disorder , by Region USD Million (2021-2026)
  • Table 112. Escitalopram tablet Others , by Region USD Million (2021-2026)
  • Table 113. Escitalopram tablet Research Studies , by Region USD Million (2021-2026)
  • Table 114. Escitalopram tablet: by Patient Age(USD Million)
  • Table 115. Escitalopram tablet Adolescent (12- 17 years) , by Region USD Million (2021-2026)
  • Table 116. Escitalopram tablet Adults (18 above) , by Region USD Million (2021-2026)
  • Table 117. Escitalopram tablet: by Dosage(USD Million)
  • Table 118. Escitalopram tablet 5mg , by Region USD Million (2021-2026)
  • Table 119. Escitalopram tablet 10mg , by Region USD Million (2021-2026)
  • Table 120. Escitalopram tablet 15mg , by Region USD Million (2021-2026)
  • Table 121. Escitalopram tablet 20mg , by Region USD Million (2021-2026)
  • Table 122. South America Escitalopram tablet, by Country USD Million (2021-2026)
  • Table 123. South America Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 124. South America Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 125. South America Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 126. Brazil Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 127. Brazil Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 128. Brazil Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 129. Argentina Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 130. Argentina Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 131. Argentina Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 132. Rest of South America Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 133. Rest of South America Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 134. Rest of South America Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 135. Asia Pacific Escitalopram tablet, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 137. Asia Pacific Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 138. Asia Pacific Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 139. China Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 140. China Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 141. China Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 142. Japan Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 143. Japan Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 144. Japan Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 145. India Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 146. India Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 147. India Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 148. South Korea Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 149. South Korea Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 150. South Korea Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 151. Taiwan Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 152. Taiwan Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 153. Taiwan Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 154. Australia Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 155. Australia Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 156. Australia Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 160. Europe Escitalopram tablet, by Country USD Million (2021-2026)
  • Table 161. Europe Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 162. Europe Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 163. Europe Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 164. Germany Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 165. Germany Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 166. Germany Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 167. France Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 168. France Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 169. France Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 170. Italy Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 171. Italy Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 172. Italy Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 173. United Kingdom Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 174. United Kingdom Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 175. United Kingdom Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 176. Netherlands Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 177. Netherlands Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 178. Netherlands Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 179. Rest of Europe Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 180. Rest of Europe Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 181. Rest of Europe Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 182. MEA Escitalopram tablet, by Country USD Million (2021-2026)
  • Table 183. MEA Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 184. MEA Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 185. MEA Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 186. Middle East Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 187. Middle East Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 188. Middle East Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 189. Africa Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 190. Africa Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 191. Africa Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 192. North America Escitalopram tablet, by Country USD Million (2021-2026)
  • Table 193. North America Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 194. North America Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 195. North America Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 196. United States Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 197. United States Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 198. United States Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 199. Canada Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 200. Canada Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 201. Canada Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 202. Mexico Escitalopram tablet, by Application USD Million (2021-2026)
  • Table 203. Mexico Escitalopram tablet, by Patient Age USD Million (2021-2026)
  • Table 204. Mexico Escitalopram tablet, by Dosage USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Escitalopram tablet: by Application USD Million (2015-2020)
  • Figure 5. Global Escitalopram tablet: by Patient Age USD Million (2015-2020)
  • Figure 6. Global Escitalopram tablet: by Dosage USD Million (2015-2020)
  • Figure 7. South America Escitalopram tablet Share (%), by Country
  • Figure 8. Asia Pacific Escitalopram tablet Share (%), by Country
  • Figure 9. Europe Escitalopram tablet Share (%), by Country
  • Figure 10. MEA Escitalopram tablet Share (%), by Country
  • Figure 11. North America Escitalopram tablet Share (%), by Country
  • Figure 12. Global Escitalopram tablet share by Players 2020 (%)
  • Figure 13. Global Escitalopram tablet share by Players (Top 3) 2020(%)
  • Figure 14. Global Escitalopram tablet share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novell Pharmaceutical Labs (Indonesia) Revenue, Net Income and Gross profit
  • Figure 17. Novell Pharmaceutical Labs (Indonesia) Revenue: by Geography 2020
  • Figure 18. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 19. H. Lundbeck A/S (Denmark) Revenue: by Geography 2020
  • Figure 20. Forest Laboratories Inc. (US) Revenue, Net Income and Gross profit
  • Figure 21. Forest Laboratories Inc. (US) Revenue: by Geography 2020
  • Figure 22. Biofarm (Poland) Revenue, Net Income and Gross profit
  • Figure 23. Biofarm (Poland) Revenue: by Geography 2020
  • Figure 24. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 25. Lupin (India) Revenue: by Geography 2020
  • Figure 26. Amneal Pharmaceuticals, LLC (US) Revenue, Net Income and Gross profit
  • Figure 27. Amneal Pharmaceuticals, LLC (US) Revenue: by Geography 2020
  • Figure 28. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 30. Silarx Pharmacueticals (US) Revenue, Net Income and Gross profit
  • Figure 31. Silarx Pharmacueticals (US) Revenue: by Geography 2020
  • Figure 32. Apotex Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 33. Apotex Inc. (Canada) Revenue: by Geography 2020
  • Figure 34. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 35. Sun Pharma (India) Revenue: by Geography 2020
  • Figure 36. Global Escitalopram tablet: by Application USD Million (2021-2026)
  • Figure 37. Global Escitalopram tablet: by Patient Age USD Million (2021-2026)
  • Figure 38. Global Escitalopram tablet: by Dosage USD Million (2021-2026)
  • Figure 39. South America Escitalopram tablet Share (%), by Country
  • Figure 40. Asia Pacific Escitalopram tablet Share (%), by Country
  • Figure 41. Europe Escitalopram tablet Share (%), by Country
  • Figure 42. MEA Escitalopram tablet Share (%), by Country
  • Figure 43. North America Escitalopram tablet Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novell Pharmaceutical Labs (Indonesia)
  • H. Lundbeck A/S (Denmark)
  • Forest Laboratories Inc. (US)
  • Biofarm (Poland)
  • Lupin (India)
  • Amneal Pharmaceuticals, LLC (US)
  • Teva Pharmaceuticals (Israel)
  • Silarx Pharmacueticals (US)
  • Apotex Inc. (Canada)
  • Sun Pharma (India)
Additional players considered in the study are as follows:
Silarx Pharmacueticals (US) , STI Pharma (US) , Aurobindo Pharma (India) , Hikma Pharmaceuticals Plc (UK) , HETERO (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation